Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Cohn, Susan L  [Clear All Filters]
Journal Article
LaFond CM, Yost A, Lankin K, Kilaru M, Cohn SL. The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022;39(5):304-316.
Friedman DNovetsky, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, Smith SA, Tonorezos ES, Wolden SL, Neglia JP, et al. Impact of Risk-Based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2024.
Desai AV, Gilman AL, Ozkaynak MFevzi, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, et al. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022:JCO2102478.
Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, et al. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016.
Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016;65:1-10.
Applebaum MA, Henderson TO, Lee SMee, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: The effects of risk-based therapy. Pediatr Blood Cancer. 2014.